CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Boehringer: what’s in and what’s out?
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
Blueprint still sees an oncology future
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
Microbiome make or break time for MaaT Pharma
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
